Paul D. Burgess - 14 Sep 2021 Form 4 Insider Report for Translate Bio, Inc.

Reporting relationship: Chief Operating Officer, CLO, Secretary
Issuer ticker: N/A
Reported as of: 14 Sep 2021
Net transaction value: -$2,729,654
SEC form: 4
Accepted by SEC: 14 Sep 2021, 19:29:46 UTC
Next SEC filing: 28 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Paul D. Burgess

Key filing fact

Paul D. Burgess filed Form 4 for Translate Bio, Inc. on 14 Sep 2021.

Key facts

This page summarizes Paul D. Burgess's Form 4 filing for Translate Bio, Inc..
6 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 14 Sep 2021, 19:29.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: -$2,729,654.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TBIO transaction

Common Stock

Sale

Transaction value: $2,729,654
Shares: -71,833
Change %: -100%
Price: $38.00^*
Shares after: 0
Date: 14 Sep 2021
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TBIO transaction Derivative

Stock Option (right to buy)

Sale

Transaction value: $0
Shares: -219,652
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 14 Sep 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 219,652
Exercise price: $7.39
Footnotes: F2, F3

TBIO transaction Derivative

Stock Option (right to buy)

Sale

Transaction value: $0
Shares: -69,953
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 14 Sep 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 69,953
Exercise price: $8.34
Footnotes: F2, F4

TBIO transaction Derivative

Stock Option (right to buy)

Sale

Transaction value: $0
Shares: -150,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 14 Sep 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,000
Exercise price: $7.95
Footnotes: F2, F5

TBIO transaction Derivative

Stock Option (right to buy)

Sale

Transaction value: $0
Shares: -150,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 14 Sep 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,000
Exercise price: $7.66
Footnotes: F2, F6

TBIO transaction Derivative

Stock Option (right to buy)

Sale

Transaction value: $0
Shares: -90,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 14 Sep 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 90,000
Exercise price: $23.82
Footnotes: F2, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021.

Footnote F2

Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.

Footnote F3

This option was granted on December 22, 2017. The shares underlying the option became fully vested on March 9, 2021.

Footnote F4

This option was granted on March 7, 2018. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on March 7, 2019 and the remainder vesting in equal monthly installments through March 7, 2022.

Footnote F5

This option was granted on March 8, 2019. This option will vest as to 25% of the shares on March 8, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 8, 2023.

Footnote F6

This option was granted on March 3, 2020. This option will vest as to 25% of the shares on December 11, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through December 11, 2023.

Footnote F7

This option was granted on March 9, 2021. This option will vest as to 25% of the shares on March 9, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares though March 9, 2025.